688506.SH上海证券交易所 · 科创板 STAR
Biokin Pharmaceutical 百利天恒
Biologics 生物制品
¥239.30−¥8.98 · −3.62%
Open 开盘
¥248.70
High 最高
¥248.70
Low 最低
¥236.09
Prev Close 昨收
¥248.28
Volume 成交量
158.9万股
Turnover 成交额
¥3.82亿
Mkt Cap 总市值
¥988亿
P/E 市盈率
−62.8×
Recent Activity 近期动态All Filings 全部公告 →
5 significant filings since 29 May 2026: 4 on buyback and 1 on major contract or bid won. The latest, on 22 Sep 2026: 四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告.
自 29 May 2026 起有 5 份重大公告：buyback 4 份、major contract or bid won 1 份。最新一份（22 Sep 2026）：四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告。
225250275300325350375
Volume 成交量
579.0万
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Key Metrics 核心指标
Reporting Period 报告期 · 30 Jun 2026 中报
Revenue 营业收入
¥1.87亿
YoY 同比 +9.43%
Net Profit 净利润
−¥16亿
YoY 同比 −46.45%
Gross Margin
毛利率
The share of each sale left after the direct cost of making the product. It shows pricing power before overheads, marketing and tax.
每笔销售扣除直接生产成本后剩下的比例，反映管理费用、营销和税之前的定价能力。In This Case 本例中Gross margin was 48.10% for the period to 30 Jun 2026 中报. Direction matters more than level, and a widening lead over peers signals a durable advantage.
方向比水平更重要，与同业差距持续拉大说明优势稳固。
每笔销售扣除直接生产成本后剩下的比例，反映管理费用、营销和税之前的定价能力。In This Case 本例中Gross margin was 48.10% for the period to 30 Jun 2026 中报. Direction matters more than level, and a widening lead over peers signals a durable advantage.
方向比水平更重要，与同业差距持续拉大说明优势稳固。
48.10%
Net Margin
净利率
The share of revenue left as profit after all costs, interest and tax.
扣除全部成本、利息和税后，营收中剩下的利润比例。In This Case 本例中Net margin was −873.95% for the period to 30 Jun 2026 中报, a net loss of ¥16亿 on ¥1.87亿 of revenue. Compare within one industry, because a supermarket at 3% can be healthier than a software company at 15%.
只在同行业内比较：3% 的超市可能比 15% 的软件公司更健康。
扣除全部成本、利息和税后，营收中剩下的利润比例。In This Case 本例中Net margin was −873.95% for the period to 30 Jun 2026 中报, a net loss of ¥16亿 on ¥1.87亿 of revenue. Compare within one industry, because a supermarket at 3% can be healthier than a software company at 15%.
只在同行业内比较：3% 的超市可能比 15% 的软件公司更健康。
−873.95%
Return on Equity
净资产收益率
The profit the company produced in the year for every 100 yuan that shareholders have in the business.
公司一年内为股东投入的每 100 元所赚取的利润。In This Case 本例中ROE was −28.92% for the period to 30 Jun 2026 中报. A sustained 15% or more is good, provided it is not propped up by heavy borrowing.
持续 15% 以上为佳，前提是不靠高负债撑起来。
公司一年内为股东投入的每 100 元所赚取的利润。In This Case 本例中ROE was −28.92% for the period to 30 Jun 2026 中报. A sustained 15% or more is good, provided it is not propped up by heavy borrowing.
持续 15% 以上为佳，前提是不靠高负债撑起来。
−28.92%
Not annualised
Debt Ratio
资产负债率
Total liabilities as a percentage of total assets. At 60%, lenders have funded three yuan of the business for every two from the owners.
总负债占总资产的百分比。60% 意味着贷款方每出三元，股东出两元。In This Case 本例中Total liabilities were 58.31% of total assets at 30 Jun 2026 中报. Read it against the industry, as a bank sits above 90% and a distiller below 30%.
要对照行业来看：银行常在 90% 以上，白酒企业则在 30% 以下。
总负债占总资产的百分比。60% 意味着贷款方每出三元，股东出两元。In This Case 本例中Total liabilities were 58.31% of total assets at 30 Jun 2026 中报. Read it against the industry, as a bank sits above 90% and a distiller below 30%.
要对照行业来看：银行常在 90% 以上，白酒企业则在 30% 以下。
58.31%
Cash Flow to Revenue
经营现金流/营收
Cash the business collected from trading, as a multiple of the revenue it booked.
经营活动收到的现金与账面营收之比。In This Case 本例中Operating cash flow was −8.20× revenue for the period to 30 Jun 2026 中报. A figure well below the net margin, period after period, means sales are being booked faster than they are paid for.
如果连续多期明显低于净利率，说明销售确认快于回款。
经营活动收到的现金与账面营收之比。In This Case 本例中Operating cash flow was −8.20× revenue for the period to 30 Jun 2026 中报. A figure well below the net margin, period after period, means sales are being booked faster than they are paid for.
如果连续多期明显低于净利率，说明销售确认快于回款。
−8.20×